{"organizations": [], "uuid": "e361c37c03cd6ed36864a66284c0d5c512ce9f3d", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180215.html", "section_title": "Archive News &amp; Video for Thursday, 15 Feb 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-cytokinetics-qtrly-net-loss-per-sh/brief-cytokinetics-qtrly-net-loss-per-share-0-75-idUSASB0C61J", "country": "US", "domain_rank": 408, "title": "BRIEF-Cytokinetics Qtrly Net Loss Per Share $0.75", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.946, "site_type": "news", "published": "2018-02-16T05:05:00.000+02:00", "replies_count": 0, "uuid": "e361c37c03cd6ed36864a66284c0d5c512ce9f3d"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-cytokinetics-qtrly-net-loss-per-sh/brief-cytokinetics-qtrly-net-loss-per-share-0-75-idUSASB0C61J", "ord_in_thread": 0, "title": "BRIEF-Cytokinetics Qtrly Net Loss Per Share $0.75", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "reuters", "sentiment": "negative"}, {"name": "cytokinetics inc", "sentiment": "negative"}, {"name": "thomson reuters", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}, {"name": "amgen", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "Feb 15 (Reuters) - Cytokinetics Inc:\n* CYTOKINETICS, INC. REPORTS FOURTH QUARTER 2017 FINANCIAL RESULTS\n* ‍ENROLLMENT IN GALACTIC-HF ON TRACK UNDER COLLABORATION WITH AMGEN; FINALIZING PLANS FOR SECOND PHASE 3 CLINICAL TRIAL IN 2018​\n* ‍COMPANY ANTICIPATES CASH REVENUE WILL BE IN RANGE OF $17 TO $23 MILLION FOR 2018​\n* QTRLY NET LOSS PER SHARE $0.75 * Q4 EARNINGS PER SHARE VIEW $-0.70 -- THOMSON REUTERS I/B/E/S\n* FY2018 REVENUE VIEW $25.6 MILLION -- THOMSON REUTERS I/B/E/S Source text for Eikon: Further company coverage:\n ", "external_links": ["http://thomsonreuters.com/en/about-us/trust-principles.html"], "published": "2018-02-16T05:05:00.000+02:00", "crawled": "2018-02-16T16:45:45.001+02:00", "highlightTitle": ""}